Could your diabetes medicine help prevent lung cancer?
NCT ID NCT07332156
Summary
This study looked at whether a newer type of diabetes medicine (SGLT2 inhibitors) might lower the risk of developing lung cancer compared to an older type (sulfonylureas) in people who have both type 2 diabetes and COPD. Researchers analyzed the existing medical records of over 21,000 patients to see which group had fewer lung cancer diagnoses. No participants received new treatment; the study only reviewed past health data to understand potential long-term effects of these common medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD, CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.